|
Volumn 21, Issue 4, 2012, Pages 455-458
|
Personalized Medicine: Patient-Predictive Panel Power
|
Author keywords
[No Author keywords available]
|
Indexed keywords
B RAF KINASE;
BCR ABL PROTEIN;
DNA TOPOISOMERASE INHIBITOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
FLT3 LIGAND;
N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;
OLAPARIB;
PACLITAXEL;
PANOBINOSTAT;
RUCAPARIB;
SELUMETINIB;
TANESPIMYCIN;
TUMOR MARKER;
VASCULOTROPIN RECEPTOR;
CANCER CELL CULTURE;
CANCER CHEMOTHERAPY;
CANCER GENETICS;
CANCER RESEARCH;
DNA DAMAGE;
DRUG TARGETING;
EWING SARCOMA;
GENE EXPRESSION;
GENE MUTATION;
HUMAN;
KIDNEY CARCINOMA;
MOLECULARLY TARGETED THERAPY;
ONCOGENE;
ONCOGENE N RAS;
PERSONALIZED MEDICINE;
PHARMACOGENOMICS;
PREDICTION;
PRIORITY JOURNAL;
SHORT SURVEY;
|
EID: 84859848953
PISSN: 15356108
EISSN: 18783686
Source Type: Journal
DOI: 10.1016/j.ccr.2012.03.030 Document Type: Short Survey |
Times cited : (13)
|
References (10)
|